Barchart.com
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Marker Therapeutics Inc (MRKR)

Marker Therapeutics Inc (MRKR)
1.2300 x 1 1.2400 x 9
Post-market by (Cboe BZX)
1.2300 -0.0200 (-1.60%) 05/05/25 [NASDAQ]
1.2300 x 1 1.2400 x 9
Post-market 1.2300 unch (unch) 15:59 ET
News & Headlines for Mon, May 5th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference GlobeNewswire - Tue Apr 1, 7:00AM CDT

MRKR : 1.2300 (-1.60%)
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results GlobeNewswire - Mon Mar 31, 7:45AM CDT

MRKR : 1.2300 (-1.60%)
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference GlobeNewswire - Tue Feb 25, 6:00AM CST

MRKR : 1.2300 (-1.60%)
Marker Therapeutics, Inc. Secures $16.1 Million in Private Placement to Advance MT-601 Clinical Study for Lymphoma Treatment Quiver Quantitative, Inc. - Thu Dec 19, 2024

Marker Therapeutics secures $16.1 million through private placement to advance MT-601 clinical trials for lymphoma treatment.Quiver AI SummaryMarker Therapeutics, Inc. announced the completion of a $16.1...

MRKR : 1.2300 (-1.60%)
Marker Therapeutics Reports Promising Results from Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma Patients Quiver Quantitative, Inc. - Thu Dec 19, 2024

The APOLLO study reports positive outcomes for MT-601 in relapsed lymphoma, showing high response rates and good tolerance.Quiver AI SummaryMarker Therapeutics, Inc. provided an update on its Phase 1 APOLLO...

MRKR : 1.2300 (-1.60%)
Marker Therapeutics Announces $16.1 Million Private Placement GlobeNewswire - Thu Dec 19, 2024

MRKR : 1.2300 (-1.60%)
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma GlobeNewswire - Thu Dec 19, 2024

MRKR : 1.2300 (-1.60%)
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer GlobeNewswire - Tue Dec 17, 2024

MRKR : 1.2300 (-1.60%)
Marker Therapeutics, Inc. CEO Juan Vera to Present at Ladenburg Thalmann Virtual Symposium on December 12, 2024 Quiver Quantitative, Inc. - Tue Dec 10, 2024

Marker Therapeutics CEO Juan Vera will present at the Ladenburg Thalmann Virtual Oncology Symposium on December 12, 2024.Quiver AI SummaryMarker Therapeutics, Inc., a Houston-based clinical-stage immuno-oncology...

MRKR : 1.2300 (-1.60%)
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium GlobeNewswire - Tue Dec 10, 2024

MRKR : 1.2300 (-1.60%)

Barchart Exclusives

Trump Is Threatening 100% Tariffs on Foreign-Made Films. Should You Buy Netflix Stock on the Dip? Barchart - 1 hour ago
Netflix stock sinks as Trump announces plans of 100% tariff on foreign-made movies. Josh Brown explains why he remains bullish on NFLX shares. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
The Truth About the Death Cross: What Every Trader Should Know
Wed, May 07, 2025 5:00 PM UTC
Reserve Your Spot